🇺🇸 FDA
Pipeline program

SPI-62_DF2

SPI-62-CL-2001

Phase 2 small_molecule active

Quick answer

SPI-62_DF2 for Cushing's Syndrome is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Cushing's Syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials